Treatment of castration-resistant prostate cancer: Updates on therapeutics targeting the androgen receptor signaling pathway

Wenhui Zhu; David S. Zhu; Ravi A. Madan; James L. Gulley; William D. Figg; William L. Dahut

doi:10.1097/MJT.0b013e3181c6c0b2

Treatment of castration-resistant prostate cancer: Updates on therapeutics targeting the androgen receptor signaling pathway

Wenhui Zhu, David S. Zhu, Ravi A. Madan, James L. Gulley, William D. Figg, William L. Dahut

Research output: Contribution to journal › Review article › peer-review

7 Scopus citations

Abstract

Androgens play a critical role in the progression of castration-resistant prostate cancer through androgen receptor (AR)-regulated signaling pathways. Progress has been made in the development of potent agents designed to suppress androgen function by blocking the AR, inhibiting the synthesis of androgens, or targeting downstream AR signaling pathways. This review summarizes the development of novel therapies based on current insights into AR signaling pathways in castration-resistant prostate cancer.

Original language	English
Pages (from-to)	176-181
Number of pages	6
Journal	American Journal of Therapeutics
Volume	17
Issue number	2
DOIs	https://doi.org/10.1097/MJT.0b013e3181c6c0b2
State	Published - Mar 2010
Externally published	Yes

Keywords

Abiraterone
Androgen receptor
Castration-resistant prostate cancer
MDV3100

Access to Document

10.1097/MJT.0b013e3181c6c0b2

Cite this

@article{995e3f0f75ae4fb6bd31e9592f5a76f8,

title = "Treatment of castration-resistant prostate cancer: Updates on therapeutics targeting the androgen receptor signaling pathway",

abstract = "Androgens play a critical role in the progression of castration-resistant prostate cancer through androgen receptor (AR)-regulated signaling pathways. Progress has been made in the development of potent agents designed to suppress androgen function by blocking the AR, inhibiting the synthesis of androgens, or targeting downstream AR signaling pathways. This review summarizes the development of novel therapies based on current insights into AR signaling pathways in castration-resistant prostate cancer.",

keywords = "Abiraterone, Androgen receptor, Castration-resistant prostate cancer, MDV3100",

author = "Wenhui Zhu and Zhu, {David S.} and Madan, {Ravi A.} and Gulley, {James L.} and Figg, {William D.} and Dahut, {William L.}",

year = "2010",

month = mar,

doi = "10.1097/MJT.0b013e3181c6c0b2",

language = "English",

volume = "17",

pages = "176--181",

journal = "American Journal of Therapeutics",

issn = "1075-2765",

number = "2",

}

TY - JOUR

T1 - Treatment of castration-resistant prostate cancer

T2 - Updates on therapeutics targeting the androgen receptor signaling pathway

AU - Zhu, Wenhui

AU - Zhu, David S.

AU - Madan, Ravi A.

AU - Gulley, James L.

AU - Figg, William D.

AU - Dahut, William L.

PY - 2010/3

Y1 - 2010/3

N2 - Androgens play a critical role in the progression of castration-resistant prostate cancer through androgen receptor (AR)-regulated signaling pathways. Progress has been made in the development of potent agents designed to suppress androgen function by blocking the AR, inhibiting the synthesis of androgens, or targeting downstream AR signaling pathways. This review summarizes the development of novel therapies based on current insights into AR signaling pathways in castration-resistant prostate cancer.

AB - Androgens play a critical role in the progression of castration-resistant prostate cancer through androgen receptor (AR)-regulated signaling pathways. Progress has been made in the development of potent agents designed to suppress androgen function by blocking the AR, inhibiting the synthesis of androgens, or targeting downstream AR signaling pathways. This review summarizes the development of novel therapies based on current insights into AR signaling pathways in castration-resistant prostate cancer.

KW - Abiraterone

KW - Androgen receptor

KW - Castration-resistant prostate cancer

KW - MDV3100

UR - http://www.scopus.com/inward/record.url?scp=77949982878&partnerID=8YFLogxK

U2 - 10.1097/MJT.0b013e3181c6c0b2

DO - 10.1097/MJT.0b013e3181c6c0b2

M3 - Review article

C2 - 20019584

AN - SCOPUS:77949982878

SN - 1075-2765

VL - 17

SP - 176

EP - 181

JO - American Journal of Therapeutics

JF - American Journal of Therapeutics

IS - 2

ER -

Treatment of castration-resistant prostate cancer: Updates on therapeutics targeting the androgen receptor signaling pathway

Abstract

Keywords

Access to Document

Fingerprint

Cite this